Jump to content

BioNTech

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Renate (talk | contribs) at 21:45, 9 November 2020 (added wikilink). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

BioNTech SE
Company typePublic (Societas Europaea)
Nasdaq: BNTX
ISINUS09075V1026
IndustryBiotechnology
Founded2008; 16 years ago (2008)
Headquarters
Mainz
,
Germany
Number of locations
5
Key people
ServicesImmunotherapy
Revenue108,589,000 Euro (2019) Edit this on Wikidata
−181,518,000 Euro (2019) Edit this on Wikidata
−179,172,000 Euro (2019) Edit this on Wikidata
Total assets797,647,000 Euro (2019) Edit this on Wikidata
Number of employees
1,323
Websitebiontech.de
BioNTech headquarters in An der Goldgrube street, Mainz

BioNTech SE (/ˈbaɪ.ɒn.ˌtɛk/) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company developed an mRNA-based human therapeutic for intravenous administration, to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.[1]

History

BioNTech was founded in 2008 based on research by Uğur Şahin, Christoph Huber and Özlem Türeci. It has since been supported by a scientific advisory board under the direction of Rolf M. Zinkernagel.[1]

In September 2019, BioNTech signed an agreement with the Bill & Melinda Gates Foundation to develop HIV and tuberculosis programs to identify and develop preclinical vaccine and immunotherapy candidates for the prevention of HIV and tuberculosis infections and for the long-term antiretroviral therapy-free remission of HIV diseases.[2]

In June 2020, BioNTech received €250 million from Singapore's Temasek Holdings and other investors through a private placement of mandatory convertible bonds.[3]

COVID-19 response

See also: COVID-19 vaccine § Clinical trials started in 2020

The company is working to develop the BNT162 vaccine against SARS-CoV-2 with Pfizer[4] and Fosun.[5][6]

Pfizer and BioNTech signed contracts to supply 200 million doses of a SARS-CoV-2 vaccine for the EU,[7] 30 million doses for the United Kingdom,[8][9] 100 million doses for the United States[10] and 120 million doses for Japan,[11] if proven safe.

References

  1. ^ a b Form F-1 BioNTech SE (Report). U.S. Securities and Exchange Commission. 9 September 2019. Retrieved 13 October 2019.
  2. ^ "The Gates Foundation sees BioNTech potential to 'dramatically reduce global HIV and tuberculosis'". The Pharma Letter. 5 September 2019. Retrieved 20 September 2019.
  3. ^ Burger, Ludwig (29 June 2020). "Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech". Reuters. Frankfurt. Retrieved 2 August 2020.
  4. ^ Lovelace Jr., Berkeley (27 July 2020). "Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday". CNBC. Retrieved 2 August 2020.
  5. ^ "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Frankfurt. 15 March 2020. Retrieved 2 August 2020.
  6. ^ Burger, Ludwig (22 April 2020). "Germany approves trials of COVID-19 vaccine candidate". Reuters. Berlin. Retrieved 2 August 2020.
  7. ^ Boseley, Sarah; Oltermann, Philip (9 November 2020). "Covid-19 vaccine candidate is 90% effective, says Pfizer". The Guardian. United Kingdom. Retrieved 9 November 2020.
  8. ^ Gallagher, James (20 July 2020). "Coronavirus vaccine: UK government signs deals for 90 million doses". BBC News. Retrieved 2 August 2020.
  9. ^ Smout, Alistair (20 July 2020). "Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva". Reuters. London. Retrieved 2 August 2020.
  10. ^ Erman, Michael; Banerjee, Ankur (22 July 2020). "U.S. to pay Pfizer, BioNTech $1.95 billion for COVID-19 vaccine". Reuters. Retrieved 2 August 2020.
  11. ^ Shakil, Ismail; Mishra, Manas (31 July 2020). "Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan". Reuters. Bengaluru. Retrieved 3 August 2020.
  • Official website
  • Business data for BioNTech SE American Depository Receipts:
  • Mutanome Engineered RNA Immuno-Therapy (MERIT) Project – EU-funded initiative
  • BioNTech, official website
  • Genentec. Individualized Neoantigen-Specific Immunotherapy (iNeST)
  • Translational Oncology Mainz (TRON), official website
Retrieved from "https://en.wikipedia.org/w/index.php?title=BioNTech&oldid=987895851"